Missing the Obvious

DIRK M. NUENNINGHOFF

J Rheumatol 2009;36;1833
http://www.jrheum.org/content/36/8/1833.1

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Missing the Obvious

To the Editor:

The article by Derot and colleagues^1^ describes a 60-year-old woman with rheumatoid arthritis (RA) who developed 4 pulmonary nodules taking methotrexate (MTX) therapy^1^. MTX was discontinued. Because of uncontrolled synovitis, the patient was started on etanercept monotherapy. The authors documented marked improvement of the pulmonary nodules 21 months after the initiation of etanercept and further improvement later on. The article does not specify when exactly MTX was discontinued, but it appears this was not long before etanercept was started. The authors conclude that the etanercept likely led to shrinkage of the pulmonary nodules. In their discussion an obvious alternative conclusion was not mentioned: that the mere discontinuation of methotrexate led to the observed improvement in the pulmonary nodules. Marked improvement of rheumatoid nodules after discontinuation of MTX has been well documented^2^ and, in my own clinical experience, can be quite dramatic. Any inference about possible clinical benefit for rheumatoid nodules related to etanercept therapy needs to be strongly cautioned.

DIRK M. NUENNINGHOFF, MD, MS, Dean Clinic, Rheumatology, 1313 Fish Hatchery Road, Madison, Wisconsin 53715, USA. E-mail: nuenninghoff.dirk@tds.net

REFERENCES